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Although recent progress in understanding the biology and optimizing the treatment of acute lymphoblastic
leukemia (ALL) has improved cure rates of childhood ALL to nearly 90%, the cure rate in adult ALL remains less than
50%. The poor prognosis in adult ALL has in part been attributed to larger proportion of high-risk leukemia showing
drug resistance. Thus, identifying novel therapeutic targets in ALL is needed for further improvements in treatment
outcomes of adult ALL. Genetic aberration of chromatin-modifying molecules has been recently reported in
subtypes of ALL, and targeting components of chromatin complexes has shown promising efficacy in preclinical
studies. Suppressor of variegation 3-9 homologue 2 (SUV39H2), also known as KMT1B, is a SET-domain–containing
histone methyltransferase that is upregulated in solid cancers, but its expression is hardly detectable in normal
tissues. Here, we show that SUV39H2 is highly expressed in ALL cells but not in blood cells from healthy donors and
also that SUV39H2mRNA is expressed at significantly higher levels in bonemarrow or blood cells from patients with
ALL obtained at diagnosis compared with those obtained at remission (P = .007). In four ALL cell lines (Jurkat and
CEM derived from T-ALL and RS4;11 and REH derived from B-ALL), SUV39H2 knockdown resulted in a significant
decrease in cell viability (~77%, P b .001), likely through induction of apoptosis. On the other hand, SUV39H2
overexpression made cells more resistant to chemotherapy. We conclude that SUV39H2 is a promising therapeutic
target and further investigation of this therapeutic approach in ALL is warranted.
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Acute lymphoblastic leukemia (ALL) is a hematological malignancy
characterized by maturation arrest and overproduction of immature,
aberrant lymphoid cells. Based on the immunophenotype of the
leukemic cells, ALL is classified as either B-cell or T-cell
lymphoblastic leukemia [1,2]. The 5-year event-free survival rate is
nearly 90% in childhood ALL but only approximately 40% in adult
ALL [3–7]. Notably, the poor prognosis in adult ALL has, in part,
been attributed to a higher proportion of high-risk leukemias that
demonstrate eventual drug resistance and subsequent relapse.
Furthermore, patients of all ages with primary resistant leukemia or
whose leukemia relapses after a transient response have few effective
therapeutic options and face a dismal prognosis [8–10]. Therefore, a
better understanding of the pathogenesis and the basis of
chemoresistance is critically important to further improve the
prognosis of these high-risk leukemias [11,12].Several studies have shown that epigenetic dysregulation charac-
terized by changes in DNA methylation and histone modification
ultimately influences transcriptional regulation and oncogenic
signaling pathways in ALL [13,14]. Notably, whole-genome and
whole-exome sequencing in addition to global chromatin profiling
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epigenetic modifiers in ALL, including MLL-FP, CBP, and NSD2
[13,14]. Furthermore, aberrant amplification of genes encoding
chromatin modifiers such as EZH2, MLL5, SUV39H1, and BRD4
has also been attributed to resistance to targeted therapy in T-ALL [15].
Indeed, approaches focused on targeting components of chromatin
complexes have emerged as promising therapeutic strategies particularly
when combined with chemotherapy [14,16]. Taken together, these
emerging findings strongly suggest that chromatin modifiers may play
an important role in the development and progression of ALL.
Suppressor of variegation 3-9 homologue 2 (SUV39H2), also
known as KMT1B, is a SET-domain–containing histone methyl-
transferase that is expressed only in testis among normal tissues [17].
However, SUV39H2 has been found to be upregulated in lung,
cervical, bladder, esophageal, and prostate cancers as well as
osteosarcomas and soft tissue sarcomas [18]. SUV39H2, which has
been found to be localized in the nucleus, is known to epigenetically
regulate gene expression by selectively trimethylating histone H3 on
lysine 9 (H3K9), a modification associated with heterochromatin
formation and subsequent gene silencing [19,20]. Our recent study
has also shown that SUV39H2 methylates histone H2AX on lysine
134 and subsequently enhances the phosphorylation of H2AX on
serine 139 [18]. Phosphorylated histone H2AX (γ-H2AX) is
associated with activation of DNA-damage repair pathways and
enhanced radio and chemoresistance of cancer cells [21–25].
Here, we hypothesized that an SUV39H2-dependent pathway
might play a role in survival and proliferation of ALL cells and that
targeting the gene would result in antileukemic activity. Our
investigation aimed to characterize the expression of SUV39H2 in
ALL and examine possible biological roles of this gene in the
pathogenesis and progression of the disease.
Results
SUV39H2 Overexpression in ALL Primary Blasts and Cell Lines
To examine the potential of SUV39H2 as a therapeutic target in
ALL, we first compared SUV39H2 mRNA levels in primary cells
obtained from 30 patients with ALL as well as 9 B-ALL and 8 T-ALL
cell lines with those in normal peripheral blood mononuclear cells
(nPBMNCs) obtained from 4 healthy donors. We found that
SUV39H2 expression levels were significantly higher in ALL blasts
and cell lines than in the nPBMNCs (P b .001; Figure 1A). No
difference was observed in SUV39H2 mRNA levels between T-ALL
and B-ALL cell lines. We also assessed SUV39H2 mRNA expression
in paired bone marrow or peripheral blood samples obtained from 30
patients with ALL at diagnosis and remission. We found SUV39H2
expression to be significantly upregulated in cells obtained at the
diagnosis compared with those obtained at the remission point (P =
.007; Figure 1B). Furthermore, we analyzed SUV39H2 protein levels
in nPBMNCs obtained from four healthy donors, and four T-ALL
and three B-ALL cell lines, and found that SUV39H2 was only
detectable in the ALL cell lines. Consistently, trimethylated H3K9
(H3K9me3) was detected in ALL cell lines but not in nPBMCs from
healthy donors (Figure 1C).
TheEffect of SUV39H2KnockdownonCell Viability inALLCell Lines
To assess the biological function of SUV39H2 in ALL cells, we
first applied a loss-of-function approach using two T-ALL (Jurkat and
CEM) and two B-ALL (REH and RS4;11) cell lines. Knockdown ofSUV39H2 in these cells was confirmed by quantitative real-time
polymerase chain reaction (qRT-PCR) (Figure 2A) and Western blot
(Figure 2B) 20 and 30 hours after the transfection of siRNAs,
respectively. Cells transfected with SUV39H2 siRNA showed a
significant decrease in cell viability (~77%, P b .001) compared with
those transfected with control siRNA as assessed by Cell Counting
Kit–8 (CCK-8) assay 48 hours after the transfection (Figure 2C).
These results were also validated in Jurkat cells using a second
independent siRNA against SUV39H2 (Figure S1, A–C).
The Effect of SUV39H2Knockdown onApoptosis in ALLCell Lines
To further examine whether the decrease in cell viability with
SUV39H2 siRNA in the four ALL cell lines (Jurkat, CEM, REH, and
RS4;11) was caused by induction of apoptosis, we prepared protein
lysates 30 hours after the transfection and examined the activation of
caspase 3 byWestern blot analysis. We observed an increase in cleaved
caspase 3 in cells transfected with SUV39H2 siRNA compared with
the cells transfected with control siRNA (Figure 3A). In addition,
Annexin V and propidium iodide (PI) staining performed on the same
set of cells at 48 hours after the transfection showed a significantly
higher proportion of Annexin V/PI–positive cells in the cells
transfected with SUV39H2 siRNA than cells transfected with control
siRNA (69% vs 14%, P b .05; Figure 3, B and C).
The Effect of SUV39H2 Overexpression on Cell Sensitivity
to Chemotherapy
To further investigate the biological functions of SUV39H2 in
ALL cells, we used 293T cells to generate lentiviral particles designed
to express SUV39H2. We confirmed by Western blot analysis the
ectopic expression of SUV39H2 and the increase of H3K9m3 in the
293T cells (Figure S2A). Jurkat cells were then transduced with the
generated lentiviral particles, and SUV39H2 overexpression was
confirmed by qRT-PCR (Figure 4A) and Western blot analyses
(Figure 4B). We also confirmed the increase of H3K9m3 in
SUV39H2-overexpressing (OE) Jurkat cells by Western blot analysis
(Figure 4, B and C). In addition, we observed a reduction in the
expression levels of downstream target genes (H19 and CD2) [26] in
SUV39H2 OE Jurkat cells compared with Jurkat cells infected with
empty vector (Jurkat EV) (Figure S3). Jurkat SUV39H2 OE and
Jurkat EV cells showed no significant difference in their growth rate
(Figure 4D). However, when cells were treated with cytarabine
(Ara-C), Jurkat SUV39H2 OE cells were less sensitive to the
treatment than Jurkat EV cells (Figure 4E). Notably, calculated IC50
values of cell viability after 72 hours of cytarabine treatment were
69 nM for Jurkat EV cells and 99 nM for Jurkat SUV39H2 OE cells
(P b .001). A similar pattern of reduced sensitivity in Jurkat
SUV39H2 OE cells was observed when cells were treated with either
doxorubicin or dexamethasone (two other drugs used in the treatment
of ALL) (Figure S4, B and C). In addition, Annexin V and PI staining
showed significantly less proportion of dead cells in Jurkat SUV39H2
OE cells than in Jurkat EV cells following treatment with 100 nM
cytarabine (P = .002; Figure 4, F and G).
Discussion
Emerging evidence has implicated aberrations in chromatin modifiers
in the majority of cancer cells. In particular, dysregulation of histone
H3 lysine methyltransferases and demethylases has been shown to
play a role in leukemogenesis. Increase of H3K9 methylation as well
as DNA methylation, partly attributed to inactivation of histone
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Figure 1. SUV39H2mRNAexpression is upregulated inALL. (A) SUV39H2mRNA levels in PBMNCsobtained from four healthy donors, primary
blasts from30 patientswith ALL, aswell as ALL cell lines (B-ALL, n=9 and T-ALL, n=8) asmeasured by RT-PCR. (B) SUV39H2mRNA levels in
paired samples obtained at diagnosis and at remission from patients with ALL (n= 30) as measured by RT-PCR. (C) Comparison of SUV39H2
and H3K9me3 protein expression in PBMNCs obtained from four healthy donors with that in ALL cell lines (B-ALL, n= 3 and T-ALL, n= 4) by
Western blot analyses. mRNA levels were normalized to B2M expression levels. P values were calculated using Student’s t test (***P b .001).
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differentiation of hematopoietic cells [27]. Furthermore, mutations
in histone methyltransferase enhancer of zeste homologue 2 (EZH2)
has been documented in a wide variety of B- and T-cell
lymphoproliferative disorders [28,29]. Whole-genome and subse-
quent target sequencing studies of early T-cell precursor ALL have
also identified high-frequency somatic alterations in histone-
modyifying genes such as EZH2, EED, SUZ12, SETD2, and
EP300 [30–32]. It is plausible that targeting components of
chromatin repressor complexes that are upregulated in cancer cellsmay be potentially effective in treating lymphoid malignancies,
including ALL. Indeed, components of chromatin complexes such as
HDAC and EZH2 have been extensively investigated as drug targets
in leukemia, and in vitro and in vivo results confirmed that they are
promising targets for novel drug development [16,29,33–36].
SUV39H2 governs methylation of H3K9 in heterochromatic
regions as a part of repressor chromatin-remodeling complexes
resulting in silencing of gene expression. SUV39H2 was originally
identified as an embryonic- and testis-specific histone methyltrans-
ferase [19] but was found to be upregulated in lung cancer. It was also
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Figure 2. SUV39H2 knockdown decreased cell viability in ALL cell lines. (A) SUV39H2 mRNA expression, (B) protein expression, and
(C) cell viability in Jurkat, CEM, REH, and RS4;11 cells transfected with SUV39H2 siRNA(#2 and 4) or control siRNA. mRNA levels were
normalized to B2M expression levels. Data are presented as mean ± SE; P values were calculated using Student’s t test (***P b .001).
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tissues except in the testis [18]. Here we have demonstrated that
SUV39H2 was upregulated in the majority of ALL cell lines and in
leukemia cells from adults with newly diagnosed ALL. We detected
much higher expression levels of this gene in leukemia blasts obtained
at diagnosis than in cells obtained from marrows or peripheral blood
following induction of remission. ALL cells derived from both B-cell
and T-cell lineages expressed significantly higher level of SUV39H2
than mononuclear cells obtained from healthy donors. These
observations suggest that the upregulation of SUV39H2 in ALL
cells is involved in leukemogenesis. Consistent with this hypothesis,
we revealed that knockdown of SUV39H2 in ALL cell lines resulted
in a significant decrease in cell viability associated with the
enhancement of apoptosis. Although SUV39H2 overexpression in
Jurkat cells did not result in increased cell proliferation, interestingly,we found that SUV39H2 overexpression resulted in cytarabine,
doxorubicin, and dexamethasone chemoresistance in Jurkat cells.
This finding is consistent with our recent report showing that
knockdown of SUV39H2 increased the sensitivity of HeLa cells to
doxorubicin by suppression of H2AX methylation and subsequent
suppression of production of γ-H2AX [18], a DNA-damage marker
that accumulates at sites of double strand breaks and triggers the
DNA damage response signaling cascade [22,37]. The potential for
synergy using drugs targeting components of the repressor chromatin
complexes, which are upregulated in cancer cells, with chemotherapy
(for example, HDAC inhibitors in combination with cytarabine) has
been demonstrated previously [16]. However, toxicity and selectivity
hurdles facing clinical development of some of these combinational
approaches suggest that identifying new targets may provide an
alternative therapeutic strategy.
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increase of cell death upon its silencing, targeting SUV39H2 in ALL
may be a promising therapeutic approach particularly in combination
with DNA damage–inducing cytotoxic agents employed for
treatment of this disease. Thus, clinical investigation of the potential
of targeting SUV39H2 in ALL is warranted.
Materials and Methods
Cell lines for In Vitro Experiments
ALL cell lines were obtained from American Type Culture
Collection. Cells are tested and authenticated by DNA profiling for
polymorphic short tandem-repeat markers. Cells were passaged in our
laboratory for fewer than 6 months after receipt. Cells were cultured
in RPMI 1640 medium (Life Technologies) supplemented with 10%FBS (Life Technologies). List of cell lines used in this study is shown
in the supplementary material (Table 1).
Patient Samples
RNA analysis was performed on paired pre-treatment and
post-remission bone marrow/peripheral blood samples from 30
patients with ALL (age range, 17 to 73 years; median age, 41 years;
10 females and 20 males). Informed consent to use the tissue for
investigational studies was obtained from each patient according to
University of Chicago institutional guidelines and institutional
review board approvals.
Transient Transfection, RNA Interference
siRNA oligonucleotide duplexes were purchased from Sigma-
Aldrich for targeting the human SUV39H2 transcript, and sequences
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siRNA#2 (CUUUGGUUGUUCAUGCACA), and siRNA#4
(CUGGAAUCAGCUUAGUCAA). For control, MISSION
siRNA universal negative control 1 from Sigma-Aldrich was used.
Transient transfection of cells was performed using 1 nmol of
siRNA and 100 μl of Gene Pulser buffer per reaction, and the cells
were electroporated with a single electric pulse of 180 V for 12
milliseconds using the Bio-Rad Gene Pulse Xcell (Bio-Rad).
RNA Extraction, RNA Expression Quantification
Total RNA was extracted using Trizol reagent (Life Technologies).
SUV39H2 mRNA expression in ALL cell lines and primary cells was
measured by the ViiA 7 system according to the manufacturer's
instructions. Each cDNA was synthesized using SuperScript III
reagents (Life Technologies) according to the manufacturer's
instructions. qRT-PCR was performed using commercially available
TaqMan Gene Expression Assay probes or Sigma-Aldrich SYBR
Green probes with the ViiA 7 system (Life Technologies). The
expression levels were normalized to B2M gene.
Western Blot Analysis and Antibodies
Samples were prepared from the cells lysed with CelLytic M cell
lysis reagent (Sigma-Aldrich) or NE-PER reagent (Thermo Scientific)containing a complete protease inhibitor cocktail (Roche Applied
Science). Total proteins were separated by electrophoresis on 4% to
12% gradient PAGE gels (Bio-Rad) and transferred to polyvinylidine
difluoride membrane (GE Healthcare). Proteins of interest were
detected by incubating membrane with horseradish peroxidase–
conjugated antibodies (Santa Cruz) and visualized with enhanced
chemiluminescence (GE Healthcare) or SuperSignal West Dura
Chemiluminescent Substrate (Thermo Scientific). The following
antibodies were used: rabbit polyclonal SUV39H2 antibody
(ab71683; Abcam), rabbit polyclonal H3 antibody (ab1791;
Abcam), rabbit polyclonal H3K9me3 antibody (ab8898; Abcam),
caspase-3 and cleaved caspase-3 (Cell Signaling), anti-hemagglutinin
(HA) high affinity (clone 3F10; Roche Life Science), and mouse
monoclonal β-actin (AC-15; Sigma-Aldrich).
Viability and Apoptosis Analyses
For viability analysis, CCK-8 assay (Dojindo Molecular Technol-
ogies, Inc.,) was performed in a 96-well plate. A total of 5 × 104 cells
were plated per well.
For viability and apoptosis analyses, cells were collected, spun
down then washed with PBS, and resuspended in 50 μl of binding
buffer containing 2 μl of Annexin V-APC (eBioscience) and 5 μl of PI
(eBioscience). After 20-minute incubation, fluorescence was
374 Targeting SUV39H2 in ALL Mutonga et al. Translational Oncology Vol. 8, No. 5, 2015quantified by flow cytometry on a FACSCalibur instrument
(BD Biosciences).
Constructs and Viral Transduction
SUV39H2was cloned in pLVX-PuroVector (Clontech) containing a
puromycin resistance gene. HA tag sequence was added downstream of
the SUV39H2 gene. Sequence of the construct was checked by Sanger
sequencing. For the virus production, 293T cells were transfectedwith a
mix containing gag/pol vector (Addgene), pCMV-VSV-G vector
(Addgene), and pLVX construct. Medium was changed after
12 hours, and infectious virions were harvested from the culture
media at 48 and 72 hours posttransfection. Jurkat cells were then
incubated with the harvested culture media for 72 hours before the
selection of cells conferring resistance against puromycin (TOKU-E).
Proliferation Assay
Control Jurkat cells (containing an empty vector) and SUV39H2
OE Jurkat cells were suspended in 1 ml of RPMI medium
supplemented with 10% FBS at a concentration of 1 × 105 cells/ml.
Cells were then counted on days 1, 2, 3, 4, and 5 using Countess
automated cell counter (Invitrogen).
Chemosensitivity Experiments
Jurkat cells containing an empty vector (Jurkat EV) or Jurkat cells
stably overexpressing SUV39H2 (Jurkat SUV39H2 OE) were treated
with increasing doses of cytarabine or doxorubicin or dexamethasone in
a 96-well plate, eachwell containing 5 × 104 cells. At day 3 for cytarabine
and doxorubicin, and day 7 for dexamethasone, CCK-8 reagent
(Dojindo Molecular Technologies) was added to assess cell viability.
For viability and apoptosis analyses, Jurkat EV or Jurkat
SUV39H2 OE cells were treated with 100 nM cytarabine. Cells
were collected at 72 hours, and Annexin V and PI staining was
performed as described in the viability and apoptosis subsection.
Statistical Analysis
Mechanistic and biological experiments were analyzed with paired
and unpaired two-sided t tests. P values b .05 were considered
statistically significant. Experiments were performed in duplicate or
triplicate; results were presented as mean ± SE.
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